Drugs / PF530
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02474134 | Mar → Oct 2015 | multiple sclerosis | Pfenex, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02474134 ↗ |
| Known as | interferon beta-1b | “The purpose of this study is to compare the safety, tolerability, and blood levels of two interferon beta-1b products, Betaferon and PF530, in healthy volunteers.” NCT02474134 ↗ |
| Route | Subcutaneous | “Single subcutaneous administration” NCT02474134 ↗ |